Evidence map›Paper›PMID 28604782›Full record

ArticlePLoS biology2017

Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe.

François Blanquart, Chris Wymant, Marion Cornelissen, Astrid Gall, Margreet Bakker, Daniela Bezemer, Matthew Hall, Mariska Hillebregt, Swee Hoe Ong, Jan Albert and 21 more

Erratum issuedAbstract readComparative Study
In one paragraph

Article in PLoS biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Leveraging graphical model techniques to study evolution on phylogenetic networks.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Scalable Bayesian phylogenetics.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

François BlanquartDepartment of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0003-0591-2466
Chris WymantDepartment of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom.
Marion CornelissenLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands.
Astrid GallWellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom.
Margreet BakkerLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands.
Daniela BezemerStichting HIV Monitoring, Amsterdam, the Netherlands.
Matthew HallBig Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Mariska HillebregtStichting HIV Monitoring, Amsterdam, the Netherlands.
Swee Hoe OngWellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom.
Jan AlbertDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Norbert BannertDivision for HIV and other Retroviruses, Robert Koch Institute, Berlin, Germany.
Jacques FellaySchool of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Katrien FransenHIV/STI reference laboratory, WHO collaborating centre, Institute of Tropical Medicine, Department of Clinical Science, Antwerpen, Belgium.
Annabelle J GourlayDepartment of Infection and Population Health, University College London, London, United Kingdom.
M Kate GrabowskiDepartment of Epidemiology, John Hopkins University, Baltimore, Maryland, United States of America.
Barbara Gunsenheimer-BartmeyerDepartment of Infectious Disease Epidemiology, Robert Koch-Institute, Berlin, Germany.
Huldrych F GünthardDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Pia KiveläDepartment of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland.
Roger KouyosDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Oliver LaeyendeckerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, United States of America.
Kirsi LiitsolaDepartment of Health Security, National Institute for Health and Welfare, Helsinki, Finland.
Laurence MeyerINSERM CESP U1018, Université Paris Sud, Université Paris Saclay, APHP, Service de Santé Publique, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
Kholoud PorterDepartment of Infection and Population Health, University College London, London, United Kingdom.
Matti RistolaDepartment of Health Security, National Institute for Health and Welfare, Helsinki, Finland.
Ard van SighemStichting HIV Monitoring, Amsterdam, the Netherlands.
Guido VanhamVirology Unit, Immunovirology Research Pole, Biomedical Sciences Department, Institute of Tropical Medicine, Antwerpen, Belgium.
Ben BerkhoutLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands.
Paul KellamKymab Ltd, Cambridge, United Kingdom.
Peter ReissStichting HIV Monitoring, Amsterdam, the Netherlands.
Christophe FraserDepartment of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom.
BEEHIVE collaboration

Funding

International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Revealing women's hidden role as critical components of HIV transmission networks in Rakai, Uganda: an interdisciplinary approachK01AI125086 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRABOWSKI, MARY KATHRYN · 2016 to 2020
$638k
Medical Research Council MR/L01632X/1NIAID NIH HHS K01 AI125086
6 · The paper itself

Abstract

HIV-1 set-point viral load-the approximately stable value of viraemia in the first years of chronic infection-is a strong predictor of clinical outcome and is highly variable across infected individuals. To better understand HIV-1 pathogenesis and the evolution of the viral population, we must quantify the heritability of set-point viral load, which is the fraction of variation in this phenotype attributable to viral genetic variation. However, current estimates of heritability vary widely, from 6% to 59%. Here we used a dataset of 2,028 seroconverters infected between 1985 and 2013 from 5 European countries (Belgium, Switzerland, France, the Netherlands and the United Kingdom) and estimated the heritability of set-point viral load at 31% (CI 15%-43%). Specifically, heritability was measured using models of character evolution describing how viral load evolves on the phylogeny of whole-genome viral sequences. In contrast to previous studies, (i) we measured viral loads using standardized assays on a sample collected in a strict time window of 6 to 24 months after infection, from which the viral genome was also sequenced; (ii) we compared 2 models of character evolution, the classical "Brownian motion" model and another model ("Ornstein-Uhlenbeck") that includes stabilising selection on viral load; (iii) we controlled for covariates, including age and sex, which may inflate estimates of heritability; and (iv) we developed a goodness of fit test based on the correlation of viral loads in cherries of the phylogenetic tree, showing that both models of character evolution fit the data well. An overall heritability of 31% (CI 15%-43%) is consistent with other studies based on regression of viral load in donor-recipient pairs. Thus, about a third of variation in HIV-1 virulence is attributable to viral genetic variation.

Indexed as

Genetic VariationGenome, ViralModels, GeneticAdultAgedCohort StudiesEuropeEvolution, MolecularFemaleGenome-Wide Association StudyHIV-1HIV InfectionsHIV SeropositivityHuman Immunodeficiency Virus ProteinsHumansMaleHuman Immunodeficiency Virus Proteins

Identifiers

PMID28604782
PMCPMC5467800

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.